M
0.764
0.03 (4.60%)
| Previous Close | 0.730 |
| Open | 0.720 |
| Volume | 116,711 |
| Avg. Volume (3M) | 100,040 |
| Market Cap | 32,088,066 |
| Price / Book | 3.97 |
| 52 Weeks Range |
| Diluted EPS (TTM) | -0.470 |
| Total Debt/Equity (MRQ) | 0.04% |
| Current Ratio (MRQ) | 12.85 |
| Operating Cash Flow (TTM) | -6.14 M |
| Levered Free Cash Flow (TTM) | -3.26 M |
| Return on Assets (TTM) | -193.30% |
| Return on Equity (TTM) | -355.82% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - General (US) | Mixed | Bullish |
| Drug Manufacturers - General (Global) | Mixed | Bullish | |
| Stock | MIRA Pharmaceuticals, Inc. | Mixed | Mixed |
AIStockmoo Score
0.3
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.0 |
| Average | 0.33 |
|
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Investment Style | Small Value |
| % Held by Insiders | 19.68% |
| % Held by Institutions | 5.60% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| First American Bank | 30 Jun 2026 | 60,000 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |